How many insider trades does FilingIQ track for IMDX?

FilingIQ tracks 31 Form 4 insider transactions for IMDX (Insight Molecular Diagnostics Inc.), covering filings from Jul 1, 2025 onwards. 21 of those were filed in the last 90 days.

Are IMDX insiders net buyers or net sellers?

Across the full Form 4 history for IMDX, 14 transactions (45%) were open-market purchases and 0 (0%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does IMDX insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is IMDX in?

Insight Molecular Diagnostics Inc. (IMDX) is classified in the Healthcare sector, specifically Diagnostics & Research, with a current market capitalisation of $166.79M.

IMDX insider trading

NasdaqCM Healthcare

Insight Molecular Diagnostics Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

Last 90 days

Buys / sells

45% / 0%

Market cap

$166.79M

About Insight Molecular Diagnostics Inc.

Insight Molecular Diagnostics Inc. operates as a precision diagnostics company in the United States and internationally. The company develops and commercializes laboratory developed tests, kitted research use only tests, and kitted clinical tests. It is developing DetermaCNI, a blood-based monitoring tool that detects progression early after one cycle cancer treatment; and DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. The company also offers GraftAssureCore test, a blood test designed to measure dd-cfDNA using a novel PCR-based measurement platform, for potential patient registrants; GraftAssureIQ, a transplant monitoring assay to measure the donor-derived cell-free DNA; and GraftAssureDx, a decentralized transplant monitoring levels of donor-derived cell-free DNA in plasma following kidney transplantation to aid in the assessment of the probability of allograft rejection at the time of testing in conjunction with standard clinical assessments. In addition, it provides testing services for biomarker discovery, assay design and development, clinical trial support, and various biomarker tests. The company has a collaboration agreement with Bio-Rad Laboratories, Inc. for the development and commercialization of research use only and in vitro diagnostics kitted transplant products using Bio-Rad's ddPCR instruments and reagents. The company was formerly known as OncoCyte Corporation and changed its name to Insight Molecular Diagnostics Inc. in June 2025. Insight Molecular Diagnostics Inc. was incorporated in 2009 and is based in Nashville, Tennessee.

Company website: www.imdxinc.com

IMDX insider activity at a glance

FilingIQ has scored 31 insider transactions for IMDX since Jul 1, 2025. The most recent filing in our index is dated Apr 27, 2026.

Across the full history, 14 open-market purchases and 0 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on IMDX insider trades is 54.0/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live IMDX trades on FilingIQ Raw filings on SEC EDGAR

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

BMY 185

BRISTOL MYERS SQUIBB CO

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

VTRS 165

Viatris Inc

Frequently asked

How many insider trades does FilingIQ track for IMDX?: FilingIQ tracks 31 Form 4 insider transactions for IMDX (Insight Molecular Diagnostics Inc.), covering filings from Jul 1, 2025 onwards. 21 of those were filed in the last 90 days.
Are IMDX insiders net buyers or net sellers?: Across the full Form 4 history for IMDX, 14 transactions (45%) were open-market purchases and 0 (0%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does IMDX insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is IMDX in?: Insight Molecular Diagnostics Inc. (IMDX) is classified in the Healthcare sector, specifically Diagnostics & Research, with a current market capitalisation of $166.79M.

Methodology & sources

Every IMDX insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.